New drug cocktail aims to fight tough esophageal cancer

NCT ID NCT07484724

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs (JS212, JS001, and 5-FU) in 280 people with advanced esophageal squamous cell carcinoma that cannot be cured by surgery. The goal is to see if the combo is safe and can shrink tumors or slow the disease. Participants must not have had prior systemic therapy for their cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS212 combined with JS001 and 5-FU (chemotherapy)
What this could lead to: If successful, this could lead to a new treatment option for advanced esophageal cancer that may help shrink tumors and extend survival.
What could go wrong: This is an early phase II trial, so the combination may not prove effective or safe enough for wider use. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Cancer Hospital of Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.